-

Flatiron Health Announces Carolyn Starrett as New CEO

Leader of Flatiron’s community oncology business to succeed Co-Founder Nat Turner

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced that Carolyn Starrett, leader of the company’s community oncology business, will become CEO, effective April 16.

Starrett will succeed Co-Founder/CEO Nat Turner who, along with Co-Founder/COO Zach Weinberg, will step down from Flatiron management on April 16.

“I am honored and energized by the opportunity to lead Flatiron in our next chapter,” said Starrett, who joined Flatiron in 2016. “I love Flatiron – our mission, our people, our culture. I’m excited to lead us to even greater impact on patient care and innovation in the field of real-world data, and to build a workforce that reflects the diversity of the many people who live with cancer.”

Founded in 2012, Flatiron has built the leading U.S. oncology real-world data source, from which its experts aggregate, de-identify, and curate clinical, genomic, and other data modalities for research purposes. More than 280 community cancer clinics across the United States center their practices on Flatiron’s OncoCloud platform and services, and Flatiron also partners with major academic cancer centers, more than 20 top developers of oncology therapeutics, and researchers and regulators across the United States and internationally.

“It has been a privilege to help nurture the pioneering start-up born from Nat and Zach’s vision into the global leader in real-world evidence that Flatiron is today,” said Severin Schwan, CEO of Roche Group, which acquired Flatiron as an independent affiliate in 2018. “Carolyn’s passion for Flatiron, her experience in technology and healthcare, and her ability to rally people around a shared vision are the perfect mix to lead Flatiron’s next life stage. I look forward to continued partnership and support.”

“We conducted an extensive search and could not have been happier to realize that the right candidate was already here at home,” said Turner, who will remain Chair of Flatiron’s Board of Directors. “It’s time for a new leader to take Flatiron to the next level, and I have every confidence in handing over the reins to Carolyn.”

About Flatiron

Flatiron Health is a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients today and tomorrow. Through clinical and data science, we translate patient experiences into real-world evidence to improve treatment, inform policy, and advance research. Together, we can outsmart cancer. Flatiron Health is an independent affiliate of the Roche Group. Flatiron.com @FlatironHealth

Contacts

Media:
Barbara Rosen, Director of Corporate Communications, communications@flatiron.com

Flatiron Health

Details
Headquarters: New York, NY
CEO: Carolyn Starrett
Employees: 2,500
Organization: PRI

Release Summary
Flatiron Health has announced that Carolyn Starrett will be its next CEO, succeeding Co-Founder Nat Turner.
Release Versions
Hashtags

Contacts

Media:
Barbara Rosen, Director of Corporate Communications, communications@flatiron.com

More News From Flatiron Health

Flatiron Health announces research to be presented at the 2025 San Antonio Breast Cancer Symposium

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its presence at the San Antonio Breast Cancer Symposium (SABCS) happening from December 9-12, 2025, in San Antonio, Texas. Flatiron's real-world data and research capabilities are featured across multiple acceptances, including three spotlight presentations and four poster presentations that leverage the breadth of Flatiron’s breast cancer solutions. "Breast cancer is the most common cancer in women worldwide, and every patient's journe...

Flatiron Health announces research to be presented at the 2025 European Society For Medical Oncology AI & Digital Oncology Congress

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its presence at the European Society For Medical Oncology AI & Digital Oncology Congress 2025 (ESMO AI) taking place on November 12-14 in Berlin, Germany. Flatiron’s experts will be presenting five pieces of research, in addition to leading the speaking session, “The VALID Framework for LLM-Extracted Oncology Data Quality: Comprehensive methodology for evaluating LLM-extracted real-world oncology data quality.” “Our research present...

Flatiron Health Announces Research to Be Presented at the 2025 American Society of Hematology’s Annual Meeting & Exposition

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its presence at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition happening from December 6-9, 2025, in Orlando, Florida. Flatiron's real-world data and research capabilities are featured across multiple presentations, including 12 research acceptances spanning hematologic malignancies—from CAR T cell therapy delivery and outcomes to measurable residual disease (MRD) testing patterns and treatment equity across...
Back to Newsroom